Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Turcot syndrome 1Stomach Neoplasms 1Lymphatic Metastasis 1

Interventions

pembrolizumab 10Nivolumab 9Ipilimumab 4avelumab 3Neoadjuvant Therapy 3toripalimab 2sintilimab 2durvalumab 2atezolizumab 2Specimen Handling 2Immune Checkpoint Inhibitors 2Celecoxib 2tislelizumab 1spartalizumab 1relatlimab 1regorafenib 1fludarabine phosphate 1fludarabine 1dostarlimab 1denileukin diftitox 1danvatirsen 1camrelizumab 1XELOX 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Oxaliplatin 1Megestrol Acetate 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × DNA Mismatch Repair × Clear all
NCT07625735 2026-06-04

MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer

Shanghai Zhongshan Hospital

Not yet recruiting
3,000 enrolled

Turcot syndrome, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡